Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE53.3400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots21.4500/ 1
- Ask / Lots84.8100/ 1
- Open / Previous Close--- / 53.3400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 354 | 50.64 |
| 09:34 ET | 713 | 50.64 |
| 09:38 ET | 100 | 50.45 |
| 09:41 ET | 100 | 50.65 |
| 09:43 ET | 880 | 50.207 |
| 09:48 ET | 974 | 50.0293 |
| 09:50 ET | 2162 | 50.455 |
| 09:56 ET | 800 | 50.695 |
| 09:59 ET | 300 | 50.42 |
| 10:01 ET | 1584 | 50.68 |
| 10:03 ET | 600 | 50.8371 |
| 10:08 ET | 298 | 50.57 |
| 10:14 ET | 1187 | 50.76 |
| 10:26 ET | 100 | 50.79 |
| 10:28 ET | 100 | 50.53 |
| 10:30 ET | 1400 | 50.77 |
| 10:32 ET | 2300 | 50.89 |
| 10:35 ET | 310 | 50.73 |
| 10:37 ET | 400 | 50.89 |
| 10:39 ET | 1980 | 50.85 |
| 10:42 ET | 1610 | 50.77 |
| 10:44 ET | 200 | 50.82 |
| 10:46 ET | 300 | 50.87 |
| 10:48 ET | 100 | 50.845 |
| 10:50 ET | 200 | 50.86 |
| 10:51 ET | 700 | 50.71 |
| 10:53 ET | 3967 | 50.67 |
| 10:55 ET | 2300 | 51.03 |
| 10:57 ET | 1214 | 50.9 |
| 11:02 ET | 100 | 50.99 |
| 11:06 ET | 983 | 50.86 |
| 11:08 ET | 100 | 50.93 |
| 11:11 ET | 500 | 50.96 |
| 11:13 ET | 300 | 50.87 |
| 11:18 ET | 429 | 50.84 |
| 11:20 ET | 100 | 50.475 |
| 11:26 ET | 695 | 50.1001 |
| 11:27 ET | 100 | 50.245 |
| 11:29 ET | 2100 | 50.81 |
| 11:31 ET | 400 | 50.615 |
| 11:33 ET | 900 | 50.4994 |
| 11:36 ET | 100 | 50.6 |
| 11:38 ET | 403 | 50.87 |
| 11:40 ET | 400 | 50.88 |
| 11:44 ET | 100 | 50.89 |
| 11:47 ET | 500 | 50.63 |
| 11:49 ET | 100 | 50.7625 |
| 11:51 ET | 300 | 50.715 |
| 12:00 ET | 400 | 50.65 |
| 12:03 ET | 700 | 50.74 |
| 12:05 ET | 100 | 50.645 |
| 12:09 ET | 400 | 50.83 |
| 12:12 ET | 200 | 50.889 |
| 12:14 ET | 400 | 50.9 |
| 12:16 ET | 400 | 51 |
| 12:18 ET | 200 | 50.87 |
| 12:20 ET | 300 | 50.835 |
| 12:21 ET | 100 | 50.74 |
| 12:27 ET | 100 | 50.78 |
| 12:30 ET | 600 | 50.89 |
| 12:32 ET | 100 | 50.925 |
| 12:34 ET | 692 | 50.81 |
| 12:36 ET | 100 | 50.885 |
| 12:38 ET | 269 | 50.93 |
| 12:39 ET | 500 | 51 |
| 12:41 ET | 500 | 50.87 |
| 12:43 ET | 600 | 50.97 |
| 12:50 ET | 100 | 50.99 |
| 12:52 ET | 915 | 50.99 |
| 12:57 ET | 600 | 50.95 |
| 12:59 ET | 900 | 51 |
| 01:01 ET | 12300 | 51.14 |
| 01:03 ET | 600 | 51.15 |
| 01:06 ET | 700 | 51.12 |
| 01:08 ET | 520 | 51.11 |
| 01:12 ET | 300 | 51.06 |
| 01:17 ET | 1913 | 50.98 |
| 01:21 ET | 100 | 50.97 |
| 01:24 ET | 200 | 50.865 |
| 01:26 ET | 100 | 50.94 |
| 01:28 ET | 1000 | 50.965 |
| 01:32 ET | 1265 | 51 |
| 01:33 ET | 5217 | 51.02 |
| 01:35 ET | 704 | 51.005 |
| 01:37 ET | 300 | 51.0175 |
| 01:42 ET | 200 | 51.08 |
| 01:44 ET | 200 | 50.97 |
| 01:46 ET | 1000 | 51.015 |
| 01:48 ET | 1756 | 50.77 |
| 01:50 ET | 200 | 50.84 |
| 01:51 ET | 300 | 50.77 |
| 01:53 ET | 100 | 50.855 |
| 01:57 ET | 200 | 50.855 |
| 02:00 ET | 100 | 50.86 |
| 02:02 ET | 3095 | 51.655 |
| 02:04 ET | 1100 | 51.41 |
| 02:08 ET | 1300 | 51.88 |
| 02:09 ET | 700 | 51.365 |
| 02:11 ET | 400 | 51.27 |
| 02:13 ET | 2000 | 51.01 |
| 02:15 ET | 3818 | 51.1543 |
| 02:18 ET | 7139 | 51.15 |
| 02:20 ET | 1900 | 51.16 |
| 02:22 ET | 11455 | 51.26 |
| 02:24 ET | 1300 | 51.15 |
| 02:26 ET | 400 | 51.12 |
| 02:27 ET | 700 | 51.15 |
| 02:29 ET | 9500 | 51.0775 |
| 02:31 ET | 5510 | 51.365 |
| 02:33 ET | 800 | 51.69 |
| 02:36 ET | 300 | 51.88 |
| 02:38 ET | 1452 | 52.08 |
| 02:40 ET | 400 | 52.35 |
| 02:42 ET | 1555 | 52.44 |
| 02:44 ET | 2203 | 52.23 |
| 02:45 ET | 3000 | 52.24 |
| 02:47 ET | 2296 | 52.43 |
| 02:49 ET | 1000 | 52.405 |
| 02:51 ET | 100 | 52.55 |
| 02:54 ET | 1400 | 52.87 |
| 02:56 ET | 700 | 52.88 |
| 02:58 ET | 778 | 53.16 |
| 03:00 ET | 2900 | 52.855 |
| 03:02 ET | 1805 | 52.82 |
| 03:03 ET | 1823 | 52.78 |
| 03:05 ET | 900 | 52.53 |
| 03:07 ET | 1000 | 52.5 |
| 03:09 ET | 770 | 52.66 |
| 03:12 ET | 100 | 52.83 |
| 03:14 ET | 1049 | 53.14 |
| 03:16 ET | 2400 | 53.47 |
| 03:18 ET | 550 | 53.45 |
| 03:20 ET | 2100 | 53.15 |
| 03:21 ET | 2000 | 53.005 |
| 03:23 ET | 2763 | 53.12 |
| 03:25 ET | 2700 | 53.35 |
| 03:27 ET | 8729 | 53.58 |
| 03:30 ET | 2311 | 53.315 |
| 03:32 ET | 2400 | 53.15 |
| 03:34 ET | 1997 | 53.25 |
| 03:36 ET | 6612 | 53.025 |
| 03:38 ET | 1254 | 52.92 |
| 03:39 ET | 2548 | 53.055 |
| 03:41 ET | 4279 | 53.135 |
| 03:43 ET | 1300 | 53.13 |
| 03:45 ET | 6593 | 53.25 |
| 03:48 ET | 6600 | 53.315 |
| 03:50 ET | 6739 | 53.465 |
| 03:52 ET | 7880 | 53.39 |
| 03:54 ET | 4031 | 53.3 |
| 03:56 ET | 19620 | 53.49 |
| 03:57 ET | 9251 | 53.67 |
| 03:59 ET | 157985 | 53.34 |
Sep 12, 2024
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit, from 7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 9, 2024
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesPress Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.1B | -23.8x | --- |
Iovance Biotherapeutics Inc | 3.1B | -6.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.6x | --- |
MoonLake Immunotherapeutics | 3.4B | -58.7x | --- |
Dyne Therapeutics Inc | 3.4B | -9.6x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -23.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
